SFSuzanne Ford

Suzanne Ford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suzanne Ford has a total of 162 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying Barriers in the Prescription Pathway of Special Low-Protein Foods and Protein Substitutes for People with PKU in the UK: An Industry Perspective

    by Martina Tosi, Suzanne Ford, Anne Grimsley, Sarah Bailey, Anita MacDonald

    Background/Objectives: Timely access to protein substitutes and special low-protein foods (SLPFs) is fundamental to maintaining dietary adherence and metabolic control in phenylketonuria (PKU). Disruptions within the prescription pathway may compromise the continuity of medical nutrition supply, with potential consequences for patient outcomes and health service efficiency. This study aimed to identify the most frequently reported prescription-related challenges from the perspective of UK industry stakeholders and to outline their implications for the care and dietetic practice of individuals with PKU. Methods: A structured questionnaire was distributed by the National Society for Phenylketonuria to industry representatives involved in supplying Advisory Committee on Borderline Substances (ACBS) approved protein substitutes and special low-protein foods (SPLFs). Anonymised responses were analysed descriptively to identify the types, frequency, and impact of prescription-related issues. Results: Forty-four prescribing and supply incidents were reported by specialist nutrition manufacturers and suppliers. Reported incidents affected both paediatric (54%) and adult (46%) patients, with protein substitutes accounting for the largest proportion of prescribing and supply issues (48%), followed by SLPFs (27%) and combined product issues (25%). Most reported barriers originated within primary care, particularly general practitioner (GP) practices (61%), followed by community pharmacies (21%). Thematic analysis identified five key areas of difficulty: GP prescribing barriers, prescribing errors, pharmacy and wholesaler procurement problems, supply chain and distribution challenges, and communication and care coordination failures. These challenges affected continuity of dietary treatment, increased the burden on patients, carers and healthcare professionals, generated additional financial costs, and highlighted wider inefficiencies within the prescribing and supply pathway. Fewer than half of the reported incidents were resolved (41%). Conclusions: Addressing these system-level barriers through improved prescribing processes, clearer communication pathways, and better coordination between stakeholders may enhance continuity of dietary treatment, reduce burden on patients and healthcare professionals, and support more efficient delivery of specialist nutritional care for individuals with PKU.

  • Open Access

    The Impact of Prescription Barriers to Special Low Protein Foods and Protein Substitutes on PKU Care: Findings from a National Survey of Metabolic Dietitians

    by Martina Tosi, Suzanne Ford, Anne Grimsley, Sarah Bailey, Anita MacDonald

    Background/Objectives: Timely access to protein substitutes and special low-protein foods (SLPFs) is essential for effective dietary management of phenylketonuria (PKU). As key healthcare professionals responsible for coordinating and delivering nutritional therapy, metabolic dietitians are directly involved in managing prescription-related issues that may arise within the access pathway. This study aimed to identify the main prescription-related barriers experienced by metabolic dietitians in the UK and to explore their implications for patient care, clinical workload, and the delivery of specialist PKU services. Methods: A structured questionnaire was distributed by the National Society for Phenylketonuria to dietitians involved in the care for individuals with PKU in the UK. Anonymised responses were analysed descriptively to identify the types, frequency, and impact of prescription-related issues. Results: A total of 448 responses were received from metabolic dietitians across the UK reporting prescription-related problems affecting dietary products. Most reported incidents involved children (306/446; 68.6%). Among responses specifying the affected product category (n = 443), SLPFs accounted for most reported problems (261/443; 58.9%), followed by protein substitutes (120/443; 27.1%) and finally combined protein substitute and SLPF issues (62/443; 14.0%). Qualitative analysis identified barriers across all stages of the prescribing pathway, with issues primarily relating to GP prescribing processes, home delivery and supply, pharmacy services, and broader administrative and system-related factors. These disruptions affected continuity of dietary management and metabolic care, with reported consequences including reduced access to prescribed dietary products, difficulties maintaining dietary adherence, increased patient and family burden, anxiety and frustration, and a substantial hidden workload for metabolic dietetic services. Conclusions: Prescription-related problems represented a significant barrier to timely access to essential medical foods for individuals with PKU in the UK. The findings highlight challenges across the prescribing and supply pathway that compromise access to both protein substitutes and SLPFs, impose additional burdens on patients and families, and increase workload for specialist metabolic dietetic services. Addressing these system-level barriers, alongside strengthening communication, coordination, and prescribing processes across stakeholders, may improve continuity of dietary treatment and enable more efficient delivery of specialist metabolic care.

  • Open Access

    How Well Is Blood Phenylalanine Controlled in Maternal PKU in Europe? Results from 102 Pregnancies

    by Alex Pinto, Kirsten Ahring, Manuela Ferreira Almeida, Catherine Ashmore, Sarah Bailey, Amaya Bélanger-Quintana, Alberto Burlina, Duncan Cole, Clare Dale, Anne Daly, et al.

    Background/Objectives: In phenylketonuria (PKU), high blood phenylalanine (Phe) levels during pregnancy negatively influence foetal organogenesis and growth, leading to maternal PKU syndrome. Pregnancies must be carefully planned in order to maintain blood Phe levels ≤ 360 µmol/L pre-conception and throughout pregnancy. Our aim was to study metabolic control in PKU pregnancies across Europe. Methods: Eleven centres managing PKU participated. Data on blood Phe levels (µmol/L), natural protein intake (g/day), protein substitute intake (g/day) and maternal weight (kg) during pregnancy were collected retrospectively from dietetic records between 2012 and 2018. Results: In total, 84 female patients with PKU, accounting for 102 pregnancies (mean age: 30.4 ± 4.8 years), participated. Of these, 7 had hyperphenylalaninemia (HPA), 26 had mild PKU, 55 had classical PKU and 14 were unclassified. Sapropterin was prescribed in two pregnancies. Only 27% (28/102) of pregnancies successfully achieved consistent blood Phe levels ≤ 360 µmol/L for at least 2 weeks pre-conception. During pregnancy, 88% of blood Phe levels were ≤360 µmol/L, with a mean Phe of 229 ± 65 µmol/L. The mean number of blood Phe samples was 60 (1.5 per week) per pregnancy. In pre-pregnancy, over a mean of 2.9 years, only 35% of blood Phe levels were ≤360 µmol/L and 61% were <600 µmol/L. Post-pregnancy, over a mean of 2.8 years, 43% of Phe levels were <600 µmol/L with mean Phe 462 ± 226 µmol/L and 724 ± 230 µmol/L, respectively. 25% (25/102) had no levels performed post-pregnancy (mean of 2.8 ± 1.6 years) compared to 7% (7/102) pre-pregnancy (mean of 2.9 ± 1.5 years). Mean prescribed Phe intake pre-/during/post-pregnancy was 810 ± 721 vs. 787 ± 552 vs. 1110 ± 722 mg/day. Natural protein intake was 17 ± 15 vs. 17 ± 11 vs. 23 ± 15 g/day. Protein equivalent from protein substitute intake was 57 ± 21 vs. 66 ± 16 vs. 50 ± 23 g/day and total protein remained stable, 73 ± 14 vs. 83 ± 14 vs. 71 ± 19 g/day (1.1 ± 0.3 vs. 1.1 ± 0.4 vs. 1.0 ± 0.4 g/kg/day). Conclusions: Although a high level of metabolic control was maintained during pregnancy, fewer than 30% of pregnancies achieved constant Phe levels ≤ 360 µmol/L prior to conception, with minimal monitoring post-pregnancy. The long-term impact on the offspring remains unknown and requires further investigation.


  • Open Access

    Blood Phenylalanine Control in Paediatric and Adult Centres in the UK: Data from 2012–2018

    by Alex Pinto, Catherine Ashmore, Jane Ash, Barbara Cochrane, Duncan Cole, Sarah Bailey, Clare Dale, Anne Daly, Charlotte Dawson, Sharon Evans, et al.

    Background: Metabolic control in phenylketonuria (PKU) is known to deteriorate with age, but national-level data describing blood phenylalanine (Phe) control across the United Kingdom (UK) are limited. Objective: To characterise blood Phe control in individuals with PKU attending UK metabolic centres. Methods: Sixteen UK centres (nine paediatric, six adult, one mixed) retrospectively extracted blood Phe results collected between 2012 and 2018. Demographic, phenotypic and monitoring-related variables were analysed. Written consent for data collection was obtained from all patients or their caregivers. Results: Data were available for 871 individuals (55% female), of whom 744 (85%) were classified as follows: classical PKU, 75%, mild PKU, 22% and hyperphenylalaninaemia, 3%. Mean blood Phe concentrations were significantly higher in adults than children (491 ± 308 vs. 303 ± 199 µmol/L; p < 0.001), and the proportion of samples within target range declined steadily with age, from 78% in children < 2 years to 36% in adults ≥ 41 years. Individuals with classical PKU had higher mean Phe concentrations and lower target attainment than those with HPA (386 vs. 300 µmol/L; 61% vs. 78%; p < 0.001), while mild PKU and HPA showed comparable control. Females generally demonstrated better metabolic control than males. More frequent dried blood spot sampling for blood Phe was strongly associated with improved metabolic control: weekly (254 ± 175 µmol/L; 82% within target), fortnightly (319 ± 207 µmol/L; 70%), monthly (397 ± 231 µmol/L; 61%), and less than monthly (624 ± 349 µmol/L; 44%). Nearly half of the blood Phe samples (47%) with recorded timing were taken in a non-fasting state. Conclusions: Achieving lifelong metabolic stability on a Phe-restricted diet alone remains challenging. These national data highlight the need for broader therapeutic options to support individuals with PKU across the lifespan.

  • Open Access

    Real-World Administration Practices of Sapropterin in Paediatric and Adults with Phenylketonuria: Results from a United Kingdom Cross-Sectional Survey

    by Martina Tosi, Sharon Evans, Alex Pinto, Richard Jackson, Catherine Ashmore, Anne Daly, Suzanne Ford, Sharon Buckley, Annabelle G. Skidmore, Anita MacDonald

    Background/Objectives: Sapropterin dihydrochloride is an established treatment option for individuals with phenylketonuria (PKU) who demonstrate responsiveness, but uncertainty persists regarding dosing frequency, timing relative to meals, the influence of dietary composition, and efficacy of different formulations. Despite widespread use in the UK, real-world administration behaviours have not previously been characterised. This study aimed to characterise sapropterin administration behaviours among people with PKU in the UK. Methods: A 31-item questionnaire was developed and disseminated via the National Society for Phenylketonuria website and social media channels. The survey captured demographic information, dosing schedules, formulation use, administration techniques, co-ingestion with food, and changes in natural protein tolerance following initiation of generic sapropterin. Results: 124 current sapropterin users completed the survey. Most respondents were caregivers of children or adolescents (68.5% aged 0–18 years). Once-daily dosing was most common (66.1%, n = 82), typically administered at breakfast, followed by twice-daily (32.3%, n = 40) and three-times-daily (1.6%, n = 2). Tablets were the predominant formulation (92.7%, n = 115); 50.4% (n = 58/115) swallowed tablets whole, while the remaining (49.6%, n = 57/115) crushed or dissolved them in water or juice. Nine respondents (7.3%, n = 9/124) used powder sachets. Most participants (75%, n = 93/124) took sapropterin with food, with both low-fat (36.6%, n = 34/93) and high-fat (26.9%, n = 24/93) meals reported. Over a third of participants (33.9%, n = 42/124) tolerated a natural protein intake >30 g/day when this was measured, and a further 15.3% (n = 19) were able to maintain a fully unrestricted protein intake without protein substitute supplementation. The magnitude of protein intake improvement was significantly greater among adults (p < 0.001), those with higher baseline natural protein intake (≥30 exchanges/day) (p < 0.001), and individuals who swallowed sapropterin tablets whole (p = 0.038). Although 71.8% (n = 89/124) were pleased with their increased natural protein allowance, many expressed a desire for further improvement. Conclusions: Substantial heterogeneity in dosing schedules, formulation handling, and co-ingestion practices highlights the absence of standardised guidance. These findings emphasise the need for clearer clinical recommendations to optimise treatment effectiveness and support consistent, equitable care.

  • Open Access

    Global Use of Casein Glycomacropeptide Protein Substitutes for Phenylketonuria (PKU): Health Professional Perspectives

    by Sharon Evans, Rani Singh, Kirsten Ahring, Catherine Ashmore, Anne Daly, Suzanne Ford, Maria Ines Gama, Maria Giżewska, Melanie Hill, Fatma Ilgaz, et al.

    Background/Objectives: Casein glycomacropeptide (cGMP) has been modified to enable its suitability as a low phenylalanine (Phe) protein substitute (PS) in phenylketonuria (PKU). No data is available about its global usage. Methods: A 60-item multiple choice and short answer/extended response questionnaire examining the use of modified cGMP in PKU was distributed globally to dietitians and physicians via web-based professional inherited metabolic disorder groups. Results: Respondents (n = 208) from 45 countries across 6 continents completed the questionnaire. Of these, 83.7% (n = 174) were dietitians/nutritionists, 14.9% (n = 31) medical doctors/physicians and 1.4% (n = 3) other health professionals, caring for both paediatric and adult patients (59.1%), paediatrics only (25.0%) or adults only (15.9%). cGMP PS were reported as not available in their centre/hospital by 19.7% (n = 41), mostly in Africa, South America, and southern and western Asia. The main reasons included lack of regulatory approval (65.8%), not promoted by manufacturers (41.5%), and cost (29.3%). An estimated 25% of represented patients globally were using cGMP PS; 78.4% (n = 163) following refusal/poor adherence with Phe-free amino acids and 54.8% (n = 114) for adult patients recommencing dietary treatment. There were concerns about the residual Phe in cGMP negatively impacting blood Phe levels in children n = 145) adjusted dietary Phe prescription according to the cGMP Phe content, particularly in regions with a higher percentage of severe PKU variants. Commonly perceived clinical advantages with cGMP were improved taste/palatability (93.2%, n = 194) and fewer gastrointestinal symptoms (55.8%, n = 116). Perceived clinical disadvantages were residual Phe (72.1%, n = 150), lack of data in children < 3 years (48.1%, n = 100), and the high energy content of some brands (45.2%, n = 94). There were concerns that cGMP PS were too high in sugar (34.1%, n = 71) and dissatisfaction or uncertainty about the adequacy of its Phe (66.3%) and amino acid (34.1%) content. Conclusions: There is global inconsistency in access to cGMP PS suitable for PKU, and in the interpretation of evidence-based research. Some professionals have significant concerns about its nutritional composition particularly residual Phe, limiting its estimated use to approximately 25% of PKU patients globally.


  • Open Access

    UK Patient Access to Low-Protein Prescription Foods in Phenylketonuria (PKU): An Uneasy Path

    by Sharon Evans, Cameron Arbuckle, Catherine Ashmore, Sarah Bailey, Giana Blaauw, Wahid Chaudhry, Clare Dale, Anne Daly, Breanna Downey, Jane Dundas, et al.

    Background: Special low-protein foods are essential in the dietary treatment of phenylketonuria (PKU). In the UK, these are available on prescription through the General Practitioners (GPs) and distributed via nutritional home delivery companies or pharmacies. Methods: A 58-item online non-validated semi-structured questionnaire was emailed to British Inherited Metabolic Disease Group (BIMDG) dietitians and dietetic support workers (DSW)/administrators working in PKU to ascertain the main system issues and errors with the supply of low-protein prescription foods (LPPF). Results: 73% (n = 53/73) of dietitians and 72% (n = 18/25) of DSW/administrators responded. A total of 80 questionnaires (representing 44 paediatric and 36 adult PKU centres) were completed. A total of 50% (n = 40/80) of respondents reported patient/caregiver problems accessing LPPF at least weekly. The most common problems were unavailable products (82%), missing LPPF in deliveries (79%), and delayed deliveries (66%). For 64% of respondents, >25% of their patients had recurring problems accessing LPPF, and 69% of respondents spent ≥1 h/week and 11% >5 h/week correcting LPPF patient supply issues. The most common foods patients experienced supply issues with were bread (96%), pasta/rice (41%) and milk replacements (35%). This was associated with GP prescription errors (65%), LPPF prescriptions sent to incorrect dispensers/suppliers (60%), and manufacturer supply issues (54%). Problems with patients/caregivers included not ordering LPPF in a timely way (81%), not responding to messages from home delivery companies (73%) and poor understanding of the ordering process (70%). The majority (93%) of respondents reported that prescription issues impacted their patients’ blood Phe control. Suggestions for improving access to LPPF included centralisation of the system to one supplier (76%) and apps for ordering LPPF (69%). Conclusions: The supply of LPPF for PKU in the UK is problematic; it may adversely affect the ability of patients to adhere to dietary management, and a review investigating patient access to LPPF is urgently required.


  • Open Access

    Adult PKU Clinics in the UK—Users’ Experiences and Perspectives

    by Fatma Ilgaz, Suzanne Ford, Michael F. O’driscoll, Anita MacDonald

    Adults with PKU require life-long management, and ideally, their care should be in a specialised adult metabolic clinic. Their outcomes and co-morbidities have received much attention, but data are lacking on their experience, satisfaction and expectations about the care they receive. This survey reports the experiences and care adults with PKU receive from specialist metabolic clinics in the UK. The online survey developed by the UK NSPKU (National Society for Phenylketonuria), was placed on the NSPKU website from February 2021 to December 2022, and was completed by adults with PKU (≥18 years) or their carers/family members. Sixty-five adult PKU patients and 9 caregivers of adult patients completed the questionnaire (63% female in total). Only 32% of respondents were following a Phe-restricted diet with protein substitute intake as prescribed; the rest were partially adherent or not on dietary restrictions. Nineteen per cent (n = 14/74) had not been reviewed in clinic for two years. Half of the respondents (50%) described their experience in adult clinics as “good”. Half of the patients were unable to contact their dietitians with questions or concerns, and only 24% considered that they received adequate support. Clinic reviews usually included anthropometric (82%) and dietary assessments (64%), discussion on management of PKU in daily life (78%) and a blood test (71%). Eighty-eight per cent reported they had at least one neurocognitive, mental health or behavioural co-morbidity but less than half of the patients reported an assessment on their neurocognitive functioning or mental health issues. Adult male patients appeared to have less detailed clinic review than females. Less than half (44%) of the respondents reported that they performed a blood spot for blood Phe at least monthly, but only 32% considered they had been informed about the risk of high Phe levels in adulthood. Although time, cost and stress related to travelling were barriers to a face-to-face review, more than 40% of patients had concerns about remote appointments. The frequency and extent of monitoring of adults with PKU, attending specialist adult services, were less than those specified by the PKU European guidelines. The care of women of reproductive age is prioritised over men. Adult metabolic health services require further attention, development and resources to provide a high standard and equitable service to patients with PKU.


  • Open Access

    Amino Acid Analyses of Plant Foods Used in the Dietary Management of Inherited Amino Acid Disorders

    by Suzanne Ford, Fatma Ilgaz, Sarah Hawker, Barbara Cochrane, Melanie Hill, Charlotte Ellerton, Anita MacDonald

    A low amino acid (AA)/protein diet is the principal treatment for many inherited amino acid disorders (IMDs). Due to their low AA content, plant foods constitute an essential part of diet therapy. However, data on their AA composition are limited, which leads to an estimation of AA intake from protein content rather than an accurate calculation of true AA intake. This study describes the AA content of a total of 73 plant foods (fruits, n = 12; vegetables, n = 51; and other plant foods, n = 10), with the analysis commissioned by the UK National Society for Phenylketonuria (NSPKU) over 15 years. For all fruits and some vegetables (e.g., rocket, watercress and pea shoots), raw samples were used during analysis. All other vegetables were cooked prior to analysis to represent the usual condition of the food at the time of serving. AA analysis was performed with ion exchange chromatography. The median percentage of protein was 2.0% [0.6–5.4%] for the fruits and vegetables analysed (n = 56), although higher in vegetables than in fruits. Each of the five reported AAs (leucine, lysine, phenylalanine, tyrosine, and methionine) supplied 1–5% per g of protein content. From the heterogeneous range of plant foods analysed, the AA/protein ratios differed significantly (2–5% in fruits and 1–9% in vegetables). There was a strong correlation between the amounts of each of the five AAs in the plant foods, but only a small, moderate correlation between the protein and AA content. Overall, this study provides data on the AA content of several plant foods, which are suitable for patients treated with a low AA/protein diet, including many novel plant options. However, only a limited range of fruits and vegetables were analysed due to the high costs of analysis. Hence, more extensive studies with an increased number of plant foods prepared by different cooking methods and replicate samples are necessary, particularly to examine the relationship between the protein and AA content in depth.


  • Open Access

    Parent’s Perception of the Types of Support Given to Families with an Infant with Phenylketonuria

    by Sophie Cassidy, Sharon Evans, Alex Pinto, Anne Daly, Catherine Ashmore, Suzanne Ford, Sharon Buckley, Anita MacDonald

    Background: A diagnosis of phenylketonuria (PKU) in an infant is a devastating and overwhelming event for their parents. Providing appropriate information and support is paramount, especially at the beginning of a child’s life. Investigating if parents are receiving the right support is important for continued care. Methodology: An online survey was distributed to explore parents’ perceptions of current support and information provided by their healthcare provider and to rate sources of other support (n = 169 participants). Results: Dietitians received the highest (85%) rate of “very helpful” support. Overall, parents found Facebook to be helpful for support but had mixed reactions when asked if healthcare professionals (HCPs) should provide advice as part of the groups. When rating the most effective learning methods, the top three were 1:1 teaching sessions (n = 109, 70%), picture books (n = 73, 50%), and written handouts (n = 70, 46%). Conclusion: Most parents are happy with the support and information they receive from their dietitian but required more support from other HCPs. Facebook groups provide parents with the social support that HCPs and their family may be unable to offer, suggesting a place for social media in future PKU care.